Compare GSK plc (GSK) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

TSM trades at $406.13, down 3.39% today, but maintains strong fundamentals with record earnings driven by AI chip demand. The stock shows a bearish technical signal near support at $404, while fundamentals reveal robust profitability with a 46.5% net margin and four consecutive quarterly EPS beats. Revenue growth accelerated to $3.81T in 2025, though valuation multiples like P/E of 36.54 appear elevated relative to historical norms.

Outlook remains positive given analyst consensus of $498.33 price target and 72% buy ratings, but risks include geopolitical tensions and high expectations priced into the stock. Cash flow strength supports dividend payments, with the next $1.11 dividend scheduled for October 2026.